Press Releases

Press Release: Online availability of Sanofi’s half-year financial report for 2024

Press Release: Sanofi Q2 - strong performance with 10% sales growth; 2024 guidance upgraded

Press Release: NEJM publishes ALTUVIIIO XTEND-Kids phase 3 data supporting its potential to transform the treatment landscape for children with severe hemophilia A

Press Release: Dupixent approved in the EU as the first-ever targeted therapy for patients with COPD

Media Update: Frexalimab new phase 2 data showed reduction of key biomarker of nerve cell damage in relapsing MS

Press Release: Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic esophagitis published in NEJM

Media Update: Riliprubart one-year results from phase 2 study underpin the potential as a first-in-class treatment in chronic inflammatory demyelinating polyneuropathy

Press Release: Availability of the Q2 2024 Aide-mémoire

Press Release: Audrey Duval Derveloy appointed Global Head of Corporate Affairs, member of Sanofi’s Executive Committee

Press Release: ISTH: Sanofi advances leadership in hemophilia with new data for ALTUVIIIO and fitusiran

Press Release: Sanofi and Biovac spearhead polio vaccine manufacturing capabilities in Africa

Press Release: ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival in combination with VRd for newly diagnosed transplant-ineligible multiple myeloma in phase 3

Media Update: Sanofi update on Zantac litigation

Press Release: Sanofi launches 2024 global Employee Stock Purchase Plan

Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPD

Press Release: Update on FDA priority review of Dupixent for the treatment of COPD patients with type 2 inflammation

Press Release: Sanofi completes acquisition of Inhibrx, Inc.

Press Release: Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible newly diagnosed multiple myeloma

Media Update: New results from rilzabrutinib phase 2 study show potential to be first advanced oral treatment for moderate-to-severe asthma

Press Release: Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration